EULAV Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

EULAV Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.9M	Buy	52,000 +3,000	+6%	+$1.54M	0.89%	34
2026 Q1	$25.7M	Hold	49,000	–	–	0.82%	42
2025 Q4	$28.5M	Sell	49,000 -2,000	-4%	-$1.02M	0.76%	44
2025 Q3	$23.4M	Buy	51,000 +20,000	+65%	+$7.46M	0.54%	64
2025 Q2	$9.38M	Buy	31,000 +21,000	+210%	+$6.26M	0.22%	102
2025 Q1	$3.31M	Hold	10,000	–	–	0.08%	147
2024 Q4	$3.09M	Hold	10,000	–	–	0.07%	149
2024 Q3	$2.12M	Hold	10,000	–	–	0.05%	158
2024 Q2	$2.8M	Sell	10,000 -1,000	-9%	-$238K	0.08%	152
2024 Q1	$2.94M	Sell	11,000 -2,000	-15%	-$471K	0.08%	154
2023 Q4	$3.01M	Buy	+13,000	New	+$2.27M	0.09%	150

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EULAV Asset Management's MDGL Position: Q2 2026 in Review

EULAV Asset Management increased its Madrigal Pharmaceuticals (MDGL) stake by 6.1% in Q2 2026, buying an estimated $1.54M and bringing the position to 52,000 shares worth $27.9M. The position accounts for 0.89% of the portfolio, ranked #34.

EULAV Asset Management first reported a position in MDGL in Q4 2023 and has held it in 11 quarters since. The position peaked at $28.5M in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

EULAV Asset Management held 52,000 shares of Madrigal Pharmaceuticals worth $27.9M as of Q2 2026.
EULAV Asset Management bought 3,000 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $1.54M.
Madrigal Pharmaceuticals made up 0.89% of EULAV Asset Management's portfolio in Q2 2026, its #34 holding.
EULAV Asset Management first reported a position in Madrigal Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
EULAV Asset Management's Madrigal Pharmaceuticals position peaked at $28.5M in Q4 2025.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on EULAV Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.